Biologics Transition Plan From US FDA Will Consider Therapeutic Equivalence Ratings
Executive Summary
While industry awaits formal guidance ahead of March 2020 transition deadline for certain protein products, FDA's Christl says plan will take into account therapeutic equivalence ratings when deciding whether products are 'deemed' licensed as full biologic applications or biosimilars.
You may also be interested in...
Insulin Market Competition: Payers Watching FDA 'Transition' Policy
FDA policies around the upcoming regulatory reclassification of insulins as biologics may impact payers' ability to leverage competition and pricing in the market, Express Scripts suggests.
FDA Biologic Transition Plan Creates 'Dead Zone' For Applications, Sponsors Fear
Industry objects to proposal that certain protein product applications pending as of March 23, 2020, will have to be resubmitted as BLAs – and to the idea that transitioned products will lose non-orphan exclusivity.
BLAs More Appealing As 'Transition' NDAs, ANDAs Set To Lose Exclusivity
Certain protein products approved under FD&C Act before March 23, 2020 would lose their remaining non- orphan exclusivity, and would not qualify for 12-year biologic exclusivity.